Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas

[1]  David Gutman,et al.  Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. , 2013, Radiology.

[2]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[3]  K. Yamashita,et al.  MR Imaging–Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status , 2016, American Journal of Neuroradiology.

[4]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[5]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[6]  H. Urbach,et al.  Molecular differences between cerebral blood volume and vessel size in glioblastoma multiforme , 2016, Oncotarget.

[7]  D. S. Williams,et al.  Magnetic resonance imaging of perfusion using spin inversion of arterial water. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[8]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[9]  Raul Rabadan,et al.  The integrated landscape of driver genomic alterations in glioblastoma , 2013, Nature Genetics.

[10]  P. Kleihues,et al.  Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. , 1988, Journal of neurosurgery.

[11]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Mitchel S Berger,et al.  Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. , 2005, Journal of neurosurgery.

[13]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[14]  A. Gupta,et al.  Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification , 2015, Clinical Neuroradiology.

[15]  David T. W. Jones,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[16]  A. Sahgal,et al.  Glioblastoma: Patterns of Recurrence and Efficacy of Salvage Treatments , 2011, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[17]  Kjell Johnson,et al.  Evaluating Methods for Classifying Expression Data , 2004, Journal of biopharmaceutical statistics.

[18]  Chul-Kee Park,et al.  IDH1 mutation of gliomas with long-term survival analysis. , 2012, Oncology reports.

[19]  S. Heiland,et al.  IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma , 2015, Scientific Reports.

[20]  Keith Paulsen,et al.  Genetics of glioblastoma: a window into its imaging and histopathologic variability. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[21]  Tae Min Kim,et al.  Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma , 2018, European Radiology.

[22]  Hye Rim Cho,et al.  Tumor blood flow from arterial spin labeling perfusion MRI: A key parameter in distinguishing high‐grade gliomas from primary cerebral lymphomas, and in predicting genetic biomarkers in high‐grade gliomas , 2013, Journal of magnetic resonance imaging : JMRI.

[23]  Scott N. Hwang,et al.  Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. , 2014, Radiology.

[24]  J. Christensen,et al.  MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. , 2010, Neuro-oncology.

[25]  S. Puget,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[26]  Chris Rorden,et al.  A novel tool to analyze MRI recurrence patterns in glioblastoma. , 2008, Neuro-oncology.

[27]  Donald S. Williams,et al.  Perfusion imaging , 1992, Magnetic resonance in medicine.

[28]  T. Cloughesy,et al.  Arterial Spin-Labeling Perfusion MRI Stratifies Progression-Free Survival and Correlates with Epidermal Growth Factor Receptor Status in Glioblastoma , 2015, American Journal of Neuroradiology.

[29]  Douglas C. Miller,et al.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.

[30]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[31]  C. Zimmer,et al.  Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. , 2003, Radiology.

[32]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[33]  S. Choi,et al.  Cerebral Blood Volume Calculated by Dynamic Susceptibility Contrast-Enhanced Perfusion MR Imaging: Preliminary Correlation Study with Glioblastoma Genetic Profiles , 2013, PloS one.